Monthly Archives: October 2021

AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)

18/10/2021 – AB Science announced that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase I/II study (AB18001) evaluating AB8939 in patients with refractory and relapsed AML

AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)

04/10/2021 – AB Science today announced that its clinical development program of masitinib in adult patients with mast cell activation syndrome (MCAS) has been approved by the U.S. Food and Drug Administration (FDA)